Education
About Us
Working with TipRanks
Follow Us
Natera (NTRA)
NASDAQ:NTRA
NTRA Analyst Ratings
Strong Buy
12 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NTRA Stock 12 Month Forecast
Average Price Target
$234.31
▼(-4.19% Downside)
| Highest Price Target$280.00 | Average Price Target$234.31 | Lowest Price Target$172.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$250
Buy
2.23%
Upside
Reiterated
12/08/25
Piper Sandler
$230
Buy
-5.95%
Downside
Reiterated
12/04/25
Morgan Stanley
$220→$265
Buy
8.36%
Upside
Reiterated
12/02/25
J.P. Morgan
$240→$250
Buy
2.23%
Upside
Reiterated
11/25/25
UBS
$218→$280
Buy
14.50%
Upside
Reiterated
11/18/25
TD Cowen
$215→$240
Buy
-1.86%
Downside
Reiterated
11/07/25
Robert W. Baird
$200→$239
Buy
-2.27%
Downside
Reiterated
11/07/25
Evercore ISI
$190→$250
Buy
2.23%
Upside
Reiterated
11/07/25
Barclays
$210→$230
Buy
-5.95%
Downside
Reiterated
11/07/25
BTIG
$210→$230
Buy
-5.95%
Downside
Reiterated
11/07/25
Craig-Hallum
―
Buy
―
Reiterated
11/06/25
Exane BNP Paribas
$172
Hold
-29.67%
Downside
Upgraded
10/27/25
Wells Fargo
$175
Hold
-28.44%
Downside
Initiated
09/22/25
Cautious Hold on Natera: Promising Growth Amid Valuation and Efficiency ConcernsWe model +16% rev CAGR from '25-28, driven by strong volume (+12% CAGR) & ASP upside, led by Oncology (+25% CAGR thru '28). Operational execution has historically been strong, having outpaced quarterly consensus revs in all but one qtr since 2020. in MRD. As first mover, NTRA's flagship Signatera test (~$1B revs) has a huge lead w/ ~90% share in the massive minimum residual disease market (~$18B TAM) that's only <10% penetrated. We see the test, which detects cancer recurrence 6-12 mos earlier than imaging, becoming a ubiquitous tool to monitor cancer burden w/ ~50% of US oncologists already using it. Competitors are emerging, but seem yrs behind. We forecast +25% rev CAGR w/ Signatera scaling to >$2B by 2030 w/ 70% GM.
RBC Capital
$255→$268
Buy
9.59%
Upside
Reiterated
09/02/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$250
Buy
2.23%
Upside
Reiterated
12/08/25
Piper Sandler
$230
Buy
-5.95%
Downside
Reiterated
12/04/25
Morgan Stanley
$220→$265
Buy
8.36%
Upside
Reiterated
12/02/25
J.P. Morgan
$240→$250
Buy
2.23%
Upside
Reiterated
11/25/25
UBS
$218→$280
Buy
14.50%
Upside
Reiterated
11/18/25
TD Cowen
$215→$240
Buy
-1.86%
Downside
Reiterated
11/07/25
Robert W. Baird
$200→$239
Buy
-2.27%
Downside
Reiterated
11/07/25
Evercore ISI
$190→$250
Buy
2.23%
Upside
Reiterated
11/07/25
Barclays
$210→$230
Buy
-5.95%
Downside
Reiterated
11/07/25
BTIG
$210→$230
Buy
-5.95%
Downside
Reiterated
11/07/25
Craig-Hallum
―
Buy
―
Reiterated
11/06/25
Exane BNP Paribas
$172
Hold
-29.67%
Downside
Upgraded
10/27/25
Wells Fargo
$175
Hold
-28.44%
Downside
Initiated
09/22/25
Cautious Hold on Natera: Promising Growth Amid Valuation and Efficiency ConcernsWe model +16% rev CAGR from '25-28, driven by strong volume (+12% CAGR) & ASP upside, led by Oncology (+25% CAGR thru '28). Operational execution has historically been strong, having outpaced quarterly consensus revs in all but one qtr since 2020. in MRD. As first mover, NTRA's flagship Signatera test (~$1B revs) has a huge lead w/ ~90% share in the massive minimum residual disease market (~$18B TAM) that's only <10% penetrated. We see the test, which detects cancer recurrence 6-12 mos earlier than imaging, becoming a ubiquitous tool to monitor cancer burden w/ ~50% of US oncologists already using it. Competitors are emerging, but seem yrs behind. We forecast +25% rev CAGR w/ Signatera scaling to >$2B by 2030 w/ 70% GM.
RBC Capital
$255→$268
Buy
9.59%
Upside
Reiterated
09/02/25
Best Analysts Covering Natera
1 Month
xxx
Success Rate
12/15 ratings generated profit
Average Return
+9.47%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +9.47% per trade.
3 Months
xxx
Success Rate
12/15 ratings generated profit
Average Return
+17.82%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +17.82% per trade.
1 Year
Success Rate
15/15 ratings generated profit
Average Return
+79.51%
reiterated a buy rating 10 months ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +79.51% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
Average Return
+172.89%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +172.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NTRA Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
2
2
2
1
0
Buy
25
23
28
23
24
Hold
5
6
6
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
31
36
29
28
Each month's total comprises the sum of three months' worth of ratings.
NTRA Financial Forecast
NTRA Stock Forecast FAQ
What is NTRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Natera’s 12-month average price target is 234.31.
What is NTRA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for NTRA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NTRA a Buy, Sell or Hold?
Natera has a consensus rating of Strong Buy which is based on 12 buy ratings, 2 hold ratings and 0 sell ratings.
What is Natera’s price target?
The average price target for Natera is 234.31. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $280.00 ,the lowest forecast is $172.00. The average price target represents -4.19% Decrease from the current price of $244.55.
The highest analyst price target is $280.00 ,the lowest forecast is $172.00. The average price target represents -4.19% Decrease from the current price of $244.55.
What do analysts say about Natera?
Natera’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of NTRA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.